Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 12/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422566 | 0.86 | EGLN3 (0.54) | EGLN3EGLN1EGLN2HDAC6CYSLTR2 | |
| SCHEMBL13367268 | 0.84 | EGLN3 (0.48) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL13367270 | 0.83 | EGLN3 (0.46) | EGLN3EGLN1EGLN2HDAC1HDAC11 | |
| SCHEMBL13367266 | 0.80 | EGLN3 (0.48) | EGLN3EGLN1EGLN2CYSLTR2THRB | |
| SCHEMBL13367220 | 0.78 | EGLN3 (0.54) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL13367267 | 0.78 | EGLN1 (0.60) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL19267291 | 0.77 | EGLN3 (0.43) | EGLN3EGLN1EGLN2HDAC1HDAC11 | |
| SCHEMBL3422070 | 0.76 | EGLN3 (0.62) | EGLN3EGLN1EGLN2 | |
| SCHEMBL3420198 | 0.75 | EGLN3 (0.53) | EGLN3EGLN1EGLN2CYSLTR2 | |
| SCHEMBL3420671 | 0.75 | EGLN3 (0.54) | EGLN3EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.